GH

Healthcare

Guardant Health, Inc.

Fundamentals5.0

Price Action6.0

News Sentiment7.0

AI Rating

6.0

Key Drivers

High gross margin
Persistent losses
Heavy leverage

AI
AI Summary

6.0

Guardant's shift from an R&D loss-maker to a commercialization-first diagnostics platform (Quest Shield distribution, biopharma CDx deals, improving gross margins) creates a credible path to compress cash burn and justify current multiples—provided Shield achieves broad payer coverage and oncology volumes scale as guided. Key actionable monitorables: weekly/monthly Shield ordering cadence and payer wins (TRICARE/ACS/PAMA exposure), quarterly gross-margin and FCF trends toward the 2027 breakeven target, and any debt-refinancing milestones that would reduce solvency risk.

CommercialPivot

ReimbursementRisk

CashFlow‍

Price Chart

Loading chart...

Financial Metrics

Revenue (TTM)

Net Income (TTM)

EPS (Q)

MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

•High gross margin
•Persistent losses
•Heavy leverage

GH combines strong unit economics and ample liquidity with persistent operating losses and heavy leverage, requiring rapid profitability or deleveraging to justify its valuation. #cash-rich

levered

Price Behavior

6.0

Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

•Downward momentum
•Broke support
•Resistance ~90s

GH is trending down over the last month (≈17% drop since 2026-02-20) and trading below its last-month average, with breakdown through Feb 20–26 support and the 2026-03-12 swing low as immediate support while resistance sits in the low–mid $90s.

bearish

neutral

Support Level: not specified (recent swing low on 2026-03-12 / range 2026-02-20–2026-02-26)

Resistance Level: $90–$95

Volatility has increased versus late-January consolidation, raising short-term trade risk

Sentiment & News

7.0

Key News Insights:

•Shield expansion
•AACR scientific push
•Mixed institutional flows

Guardant Health accelerated commercial rollout and scientific dissemination for its Shield colorectal test while institutional holdings diverged and the board approved hiring-related equity grants. #investor-divergence‍

commercial

The combined commercial momentum and scientific visibility should support revenue and perception upside, but divergent institutional trades and equity grants add short-term shareholder pressure